Q2 2025 SMS Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- SMS Pharmaceuticals Ltd (BOM:532815) reported an 18% year-on-year increase in revenues for Q2 FY25, reaching INR196.75 crores, driven by healthy volume growth across its portfolio.
- The company achieved a 20% year-on-year growth in revenue from operations for the first half of FY25, reaching INR361.2 crores, supported by a strategic focus on expanding volumes in key APIs.
- SMS Pharmaceuticals Ltd maintained steady EBITDA margins at 16% for Q2 and 18% for the first half of FY25, thanks to ongoing operational efficiency efforts.
- The company received the EDQM certificate for its Vizag facility to supply ibuprofen for Europe, reflecting its commitment to quality and compliance with global standards.
- SMS Pharmaceuticals Ltd is on track with its backward integration and capacity expansion projects, aiming for commercialization by Q4 FY25, which is expected to support long-term growth.
- Gross margins for Q2 FY25 declined to 30% due to rising raw material costs influenced by geopolitical tensions.
- The company faces ongoing pressure from broader industry challenges, impacting its financial performance.
- There is significant price pressure on one of its key products, leading to a pricing erosion of around 10% per year.
- The market for one of its JV products has consolidated, with flat or slightly declining volumes and increased competition.
- New product commercialization is delayed due to patent issues, with some products expected to take two to three years to launch.
Ladies and gentlemen, good day and welcome to SMS Pharmaceuticals Limited Q2 FY25 earnings conference call. This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions and expectations of the company as on date of this call.
These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict. (Operator Instructions) Please note that this conference is being recorded.
Today we have with us Mr. Vamsi Krishna Potluri, Executive Director; Mr. Lakshmi Narayana Tammineedi, Chief Financial Officer and Mr. Thirumalesh Tumma, Company Secretary and Compliance Officer.
I now hand the conference over to Mr. Vamsi Krishna Potluri, Executive Director. Thank you and over to you, sir.
Good afternoon and a warm welcome to you all for joining our Q2 FY25 earnings call. I hope everyone has had an opportunity to go through our financial results and investor presentation which has
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
